Today the government of Bolivia and Biolyse, a company based in Canada, signed an agreement to acquire COVID-19 vaccines manufactured by the company, if Canada grants them a compulsory license. Biolyse is a manufacturer of cancer drugs with the potential… Continue Reading
On July 19, 2018, the U.S. District Court, Northern District of California, denied a permanent injunction requested by Illumina, Inc, and instead ruled that a forward looking royalty for continued non-voluntary use of the invention, a type of compulsory license,… Continue Reading
On Thursday February 7, 2019, KEI submitted comments and intent to testify at the hearing for the 2019 US Trade Representative’s Special 301 review process. This year’s hearing will take place on Wednesday February 27, 2019 at the Office of… Continue Reading
On June 8, 2018 the Cámara de Diputados of the Chilean Congress overwhelmingly passed a resolution calling on the Ministry of Health to proceed with compulsory licenses on patents covering hepatitis C virus (HCV) drugs. Resolution No. 68, passed with… Continue Reading
KEI has joined unions, NGOs and payors on a letter sent to Senator Grassley and Sen. Feinstein, the chair and ranking member of the Judiciary Committee, thanking them for their support of the Creating and Restoring Equal Access to Equivalent… Continue Reading
KEI submitted a post-hearing submission to the USTR for the Special 301 on behalf of itself and twelve other international NGOs and academic institutions condemning recent pressures on Colombia’s legal and regulatory measures to increase access to affordable medicines, including… Continue Reading
Representative Ro Khanna (D-CA-17) was joined by 17 other members of Congress in calling upon Department of Health and Human Services Secretary Alex Azar to issue a compulsory license on patents for medications to treat hepatitis C, by exercising 28… Continue Reading
To be added, the early CLs on HIV drugs in several African countries. South Africa 2013 2003: CPTech’s 2003 reports for the RSA Competition Commission, in Hazel Tau et al.v GSK, Boehringer, et al. CPTech was the consultant to the… Continue Reading